title: Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.
authors: M Patrizia
authors: MP
authors: Carrieri
authors: Julien
authors: J
authors: Cohen
authors: Dominique
authors: D
authors: Salmon-Ceron
authors: Maria
authors: M
authors: Winnock
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D003069:Coffee; D060085:Coinfection / Q000188:drug therapy / Q000503:physiopathology; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
chemical_list: D000998:Antiviral Agents; D003069:Coffee; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a